FDA's Top Cancer Regulator Influences Replimune Rejection Amid Biotech Downturn
TL;DR Summary
San Diego's biotech industry is experiencing a downturn with job losses and increased lab vacancy rates, partly due to the FDA's rejection of Replimune's melanoma drug, which was influenced by FDA cancer chief Richard Pazdur's intervention, not Vinay Prasad.
- The story behind the Replimune rejection, and San Diego sees a biotech winter statnews.com
- FDA’s top cancer drug regulator played key role in rejection of Replimune therapy, officials say statnews.com
- After surprise CRL, Replimune says it's waiting for FDA on a path forward for cancer treatment Endpoints News
- Top FDA Cancer Regulator Intervened To Reject Replimmune’s Melanoma Drug BioSpace
- Replimune stock down after report on drug rejection (REPL) Seeking Alpha
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
1 min
vs 1 min read
Condensed
77%
168 → 39 words
Want the full story? Read the original article
Read on statnews.com